TopoisomeraseII inhibitor 23 is a potent inhibitor of topoisomerase II (topoisomeraseII) with an IC50 value of 0.94 μM. Compared to doxorubicin (IC50 of 3.08 μM), it exhibits high selectivity and superior cytotoxic effects in MCF-7, HepG2, and HCT116 cells. This compound induces cell cycle arrest at the G1 phase, leading to the inhibition of cell proliferation. It also promotes apoptosis (apoptosis) by upregulating the pro-apoptotic protein Bax and downregulating the anti-apoptotic protein Bcl-2.

Topoisomerase II inhibitor 23 (Compound IId) exhibits significant cytotoxic effects on MCF-7, HepG2, and HCT116 cells, with IC50 values of 24.52 μM, 28.92 μM, and 54.38 μM, respectively. It demonstrates high selectivity for these cells, with selectivity indices of 3.8, 3.3, and 1.7 compared to human cell line BJ cells. At a concentration of 24.52 μM for 24 hours, this inhibitor halts cell growth at the G1 phase, inhibiting the proliferation of MCF-7 cells. Additionally, it induces apoptosis by increasing Bax levels and decreasing Bcl-2 levels in MCF-7 cells. Topoisomerase II inhibitor 23 exhibits potent topoisomerase II inhibitory activity with an IC50 value of 0.94 μM, which is higher than that of doxorubicin (IC50 value of 3.08 μM).